Numinus Wellness Inc.
NUMI.TO
Toronto Stock Exchange0.05
CAD
- -
- -
Numinus Wellness Inc.
NUMI.TO
(Toronto Stock Exchange)
Recent
price
0.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Numinus Wellness Inc. (TSX: NUMI) operates as a mental healthcare company focused on advancing traditional and innovative behavioral health treatments, including safe, evidence-based psychedelic-assisted therapies. The company provides clinical research management services to academic institutions and biotechnology firms; psychedelic-assisted psychotherapy products and services; ketamine-assisted therapies for depression; traditional therapy, counseling, mindfulness programs, and virtual psychotherapy; neurological care services; transcranial magnetic stimulation (TMS); psychiatric and medical model management; laboratory services encompassing cultivation, production, and extraction of natural Psilocybe and other psychoactive fungi species, proprietary process and product development, and protocol studies for controlled psychedelics; lab testing services; and practitioner training programs. It serves patients and healthcare providers primarily through its Clinical Research Operations, Practitioner Training, Canadian Clinic Network, U.S. Clinic Network, and Corporate segments, with a target market in individuals seeking treatment for depression, anxiety, trauma, pain, PTSD, and substance use disorders. Geographically, Numinus conducts operations in Canada and the United States. Founded in 1964 and headquartered in Vancouver, British Columbia, Canada, the company maintains a presence through brands including Numinus Health, Mindspace Services, and the Neurology Center of Toronto. In November 2024, Numinus executed a definitive agreement to sell its five Utah-based U.S. wellness clinics to Stella MSO LLC for US$3.53 million, consisting of US$2.08 million at closing, US$750,000 in monthly installments through 2025, and up to US$0.70 million in deferred compensation, with the transaction closing by December 2024 to enable a strategic shift toward an asset-light model focused on the Numinus Network for clinic efficiency and reimbursement solutions. This sale includes a unique data partnership with Stella, providing ongoing access to operational data from 12 mental health clinics to develop SaaS-based clinic management tools, AI-driven solutions, insurance reimbursement support, and advanced operational efficiencies for mental health practices. The divestiture leverages Numinus' experience from serving approximately 50,000 unique patients across over 200,000 appointments and 250,000 insurance-reimbursed claims to prioritize product development in ketamine, Spravato™, and psychedelic integration therapies. In fiscal Q3 2025, revenues from Practitioner Training rose 12.3% year-over-year to $189,685, reflecting sustained demand amid the company's pivot to technology-driven solutions.